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A B S T R A C T
The heterotrimeric NF-Y complex is a pioneer factor that binds to CCAAT-genes and regulates their transcription.
NF-Y cooperates with multiple transcription factors and co-regulators in order to positively or negatively in-
fluence gene transcription. The recruitment of NF-Y to CCAAT box is significantly enriched in cancer-associated
gene promoters loci and positively correlates with malignancy. NF-Y subunits, in particular the DNA-binding
subunit NF-YA and the histone-fold subunit NF-YC, appear overexpressed in specific types of cancer.
Here we demonstrate that NF-Y subunits expression is finely regulated through transcriptional and post-
translational mechanisms thus allowing control over basal expression levels. NF-Y negatively regulates the
transcription of the genes encoding for its subunits. DNA pull-down/affinity purification assay coupled with
Mass Spectrometry identified putative co-regulators, such as Lamin A, involved in NF-YA gene transcription
level. We also evidentiate how the stability of the complex is severely affected by the absence of one subunit.
Our results identified for the first time one of the mechanisms responsible for NF-Y expression, which may be
involved in the aberrant expression and activity observed in tumor cells and other pathological conditions.
1. Introduction
The mammalian CCAAT-box transcription factor (TF) NF-Y is com-
posed by three subunits, NF-YA, NF-YB and NF-YC. The hetero-
dimerization of NF-YB and NF-YC histone-fold subunits is a prerequisite
for NF-YA association into the complex. The whole complex is able to
bind specifically to CCAAT-boxes, which occur at 30% of eukaryotic
promoters and enhancers, prevalently in tissue specific ones [1,2].
NF-Y subunits are evolutionarily strongly conserved in all eu-
karyotes [[3,4]. Although NF-Y is considered a ubiquitous TF, NF-YA
has a tissue specific expression pattern and its mRNA levels are rela-
tively constant in proliferating and differentiated cells [5,6], with the
exception of adult skeletal muscle and heart tissues [7,8]. Consistently,
NF-YA is present in proliferating myoblasts, but its expression is pro-
gressively lost during cells differentiation [7]. In contrast, NF-YA is not
expressed in freshly isolated monocytes but it is synthesized during the
maturation process [9]. NF-YA displays differential expression
throughout the cell cycle, with high levels at the onset of S phase
decreasing in G2/M [5]. The modulation of NF-YA protein expression is
mediated by the ubiquitin–proteasome degradation system: p300-
mediated acetylation at the C-terminus prevents, in part, its ubiquity-
lation and ubiquitin-dependent proteolysis [10].
Two major alternative splice variants of NF-YA have been described
NF-YAs and NF-YAl. The short isoform (NF-YAs) lacks a 28-amino acid
region within the NF-YA Glutamine-rich domain [11]. Relative NF-YAs
and NF-YAl expression levels vary in different cell types. A switch in
their abundance was documented during the differentiation of mouse
ES cells and during somatic cells reprogramming into pluripotent stem
cells [12,13]. Noticeably, while NF-YAl increases through mouse and
human embryonic cell differentiation, NF-YAs levels are reduced. Also
in human hematopoietic stem cells, NF-YAs has a demonstrated role in
the maintenance of stemness [14].
Similarly, NF-YC subunit has different isoforms arising from alter-
native spliced transcripts translated into 37, 48 and 50 kDa polypep-
tides. The expression levels of specific NF-YA and NF-YC isoforms are
strongly correlated, suggesting the presence of variously composed NF-
https://doi.org/10.1016/j.bbagrm.2018.02.008
Received 7 December 2017; Received in revised form 14 February 2018; Accepted 27 February 2018
⁎ Corresponding author.
1 These authors equally contributed to this work.
E-mail addresses: cimbriano@unimo.it, carol.imbriano@unimore.it (C. Imbriano).
Abbreviations: TF, transcription factor; MS, Mass Spectrometry; ChIP, Chromatin ImmunoPrecipitation; shRNA, Short Hairpin RNA
BBA - Gene Regulatory Mechanisms xxx (xxxx) xxx–xxx
1874-9399/ © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
Please cite this article as: Belluti, S., BBA - Gene Regulatory Mechanisms (2018), https://doi.org/10.1016/j.bbagrm.2018.02.008
Y complexes [15].
NF-Y activity is essential for cell proliferation and viability, thus the
deletion of both NF-YA alleles triggers early mouse embryo lethality
[16]. NF-Y controls the expression of numerous cell cycle-regulated and
pro/anti-apoptotic genes by binding to their proximal promoter ele-
ments [17–19]. The activity of NF-Y has been associated to the trans-
formation process: systematic studies of deregulated pathways in dif-
ferent types of cancers identified NF-Y as one of the transcription
factors orchestrating key transcriptional changes [20–22]. Significant
association between NF-Y target genes expression and poor prognosis
has been described in breast, lung, multiple myeloma and renal cancers
[23]. In low grade epithelial ovarian cancers (EOCs), the pattern of NF-
YAs isoform expression and Lamin A correlates with tumor aggres-
siveness [24]. In addition, NF-YC has been recently listed among po-
tential oncogenes since NF-YC inactivation completely abolished
choroid plexus carcinoma (CPC) initiation and maintenance [25] and it
is differentially expressed in human glioma samples, where it activates
cell proliferation [26].
We previously demonstrated that specific inactivation of NF-Y
subunits leads to different cell cycle defects: NF-YA loss triggers S-phase
defects and apoptosis, while NF-YB and NF-YC depletion delays the G2/
M progression [18]. We also observed that NF-YA inactivation results in
increased NF-YB expression, therefore we decided to investigate the
role of NF-Y in the transcriptional and non-transcriptional regulation of
its own subunits.
In this study, we show that a negative transcriptional feedback
controls the expression of genes encoding for NF-Y subunits. NF-Y ap-
pears directly associated to NF-YA, NF-YB and NF-YC genes promoters
and works as a transcriptional repressor. We used Mass Spectrometry
(MS) to identify proteins isolated on the NF-YA regulatory region by a
DNA pull-down strategy, and we demonstrate that Lamin A acts as a
negative regulator of NF-YA gene transcription. Ultimately, we ob-
served that the association of the NF-YB/NF-YC subunits is fundamental
for the complex stability against degradation.
Overall, our data highlight the importance of controlled expression
of NF-Y subunits for a proper regulation of cell proliferation and
identify mechanisms potentially involved in NF-Y complex aberrant
activation in cancer cells.
2. Materials and methods
2.1. Cell culture, treatments and lentiviral transduction
Human colon carcinoma HCT116 cells were cultured in Iscove's
Modified Dulbecco's Medium (IMDM), supplemented with 10% fetal
calf serum (FCS). Human hepatic fetal epithelial WRL-68 cells, im-
mortalized human keratinocyte HACAT cells, human cervical cancer
Hela cells, human colorectal adenocarcinoma HT-29 and SW-480 cells
were maintained in Dulbecco's Modified Eagle Medium (DMEM) with
10% FCS. Immortalized prostatic epithelial PNT1A cells were cultured
in RPMI medium additioned with 10% FCS. Protein degradation was
inhibited through administration to cell culture media of 1 μM Z-Leu-
Leu-Leu-H (MG132; Sigma-Aldrich), 5 μMN-Ac-Leu-Leu-norleucinal
(LLnL; Sigma Aldrich) and 50 μM chloroquine (CQ) for 18 h.
NF-YA, NF-YB and NF-YC inactivation was obtained by lentiviral
infection of the above-mentioned cells with pLKO.1 shRNA lentiviral
particles (MOI=4) and harvested 48 h post-infection, as previously
described [18,27]. siRNA transfections were performed as previously
reported [28]. NF-YA-DN overexpression was induced by lentiviral
delivery of pCCL-NF-YA-DN particles (MOI=4) for 48 h [8].
2.2. Immunoblots
Whole cell protein extracts were prepared by resuspending cells into
1× SDS sample buffer (25mM TrisHCl pH 6.8, 1.5 mM EDTA, 20%
glycerol, 2% SDS, 5% β-mercaptoethanol, 0.0025% Bromophenol blue).
Cytoplasmic and chromatin-enriched extracts were prepared as pre-
viously described [27,29]. For immunoblotting equivalent amounts of
extracts were resolved by SDS-PAGE, electrotransferred to PVDF
membrane (GE Healthcare) and immunoblotted with the following
primary antibodies: anti-H3 (sc-8654, Santa Cruz), anti- tubulin
(T6074, Sigma-Aldrich), anti-actin (sc-1616, Santa Cruz), anti-NF-YA
(A302–105, Bethyl lab), anti-NF-YB (Pab001, GeneSpin), anti-NF-YC
(gift of Prof. R.Mantovani), anti- LaminA/C (sc-7292×, Santa Cruz).
2.3. RNA extraction and qRT-PCR analysis
RNA was extracted from cells using RNeasy kit (Qiagen) and re-
versed transcribed with a Moloney murine leukemia virus reverse
transcriptase (Promega). Quantitative real-time PCRs were performed
using DyNAmo ColorFlash SYBR Green Master mix (Thermo Scientific)
on a Roche Light Cycler 480 II Real-time PCR instrument, with the
following oligonucleotides: h-gACTIN (F gccaacagagagaagatgactc; R
agaggcgtagagggacagc), hNF-YA (F ggaggccagctaatcacatc; R gccga-
gactcatgcaggtat), hNF-YB (F aggtgccatcaagagaaact; R
tgttgttgaccgtctgtggt), hNF-YC (F agtggcactggacagaccat; R cctgata-
caggctgggctaa). Relative fold change enrichments of transcripts were
calculated with the formula 2–(ΔΔCt), where –(ΔΔCt)= –
[(Cttarget− CtgACTIN) shNFY− (Cttarget− CtgACTIN) shCTR].
2.4. Plasmids and transfections
For each point, 150.000 HCT116 cells were seeded into 24-well
plates and transfected after 24 h using Lipofectamine 2000 (Invitrogen),
according to the protocol provided by the manufacturer. Cells were
recovered 24 h after transfection and resuspended in lysis buffer (1%
TritonX 100, 25mM GlyGly pH 7.8, 15mM MgSO4, 4mM EGTA pH 8)
for detection of luciferase activity. The results were normalized to
protein concentration (Bradford reagent, Sigma Aldrich) and % GFP
positive cells (measured by flow cytometric analysis). Three in-
dependent transfections were performed. The minimal human NF-YA
promoter reporter construct, which contains the region spanning from
−272 to +189 from NF-YA transcription start site, was generated by
digestion of the previously described pGL3b-NF-YA promoter vector
[15] with SmaI and PvuII and subsequent re-legation. For transient
overexpression of the NF-Y heterotrimer, 50 ng of each pSG5 expression
vector encoding for murine NF-YA, NF-YB and NF-YC 37 kDa subunits
were co-transfected with 150 ng of the minimal NF-YA promoter luci-
ferase construct and 100 ng of pCMV-GFP. For the overexpression of the
NF-YA dominant negative mutant, 100 ng of pSG5-NF-YA-DN vector
was transfected together with NF-YA promoter and pCMV-GFP. All the
pSG5 encoding vectors have been previously described [15,30]. Mouse
NF-YA cDNA was cloned into pSG5 via EcoRI/BglII, NF-YB via EcoRI/
BglII, NF-YC via KpnI/BamHI restriction enzymes. pCMV3-LMNA ex-
pression plasmid was purchased from Sino Biological Inc. (HG12058)
and the corresponding pCMV3-Empty vector was generated by re-
moving the coding region via HindIII and XbaI digestion. Transient
protein overexpression versus basal levels was verified by western blot.
2.5. Chromatin immunoprecipitation (ChIP)
Chromatin was prepared 48 h post-shRNA infection and ChIPs were
performed as previously described [18]. 4 μg of the following anti-
bodies were added to each IP and incubated overnight at 4 °C: anti-NF-
YA (A302–105, Bethyl lab), anti- LaminA/C (sc-7292×, Santa Cruz),
anti-Histone H4Ac (06–866, Millipore), anti-NF-YB (Pab001, Gene-
Spin), anti-Histone H3K4me3 (39,159, Active Motif), anti-Histone
H3K56ac (Active Motif, 39,281), anti-TFIID (TBP) (sc-204, Santa Cruz).
Immunoprecipitated DNA was resuspended in TE buffer, and real-time
PCRs were performed using DyNAmo ColorFlash SYBR Green Master
mix (Thermo Scientific,) on a Roche Light Cycler 480 II Real-time PCR
instrument, with the following primers: hNF-YA (F tcccctttgttcgggttc; R
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attggctcctcacactcacc), hNF-YB (F gttccttcgcagccatttt; R gcgagaca-
caaacctccaat), hNF-YC P1 (F gacctggcaccttattggac; R
cctctcttcccccttaaagc), hSAT CHR11 as control for non-specific interac-
tions (F ggcgaccaatagccaaaaagtgag; R caattatcccttcggggaatcgg). Results
are presented as % of immunoprecipitated DNA or as Relative fold
change of immunoprecipitated DNA in shNF-YA versus shCTR cells. The
% of immunoprecipitated DNA was calculated with the formula 2-
(ΔCt), where−ΔCt=−(CtIP− CtINPUT) and the Relative fold change
was calculated with the formula 2-(ΔΔCt), where −ΔΔCt=−
[(CtIP− CtINPUT)shNFYA− (CtIP− CtINPUT)shCTR].
2.6. DNA pull-down/affinity purification assay
A biotinylated 477 bp proximal hNF-YA promoter probe was ob-
tained by PCR with Phusion High-Fidelity DNA Polymerase (F530,
Thermo Scientific) and a 5′-biotinylated primer (IDT, Integrated DNA
Technologies). The amplification was performed using a 2-step ther-
mocycling protocol, as indicated by the manufacturer, and a typical
50 μl reaction containing 1 ng of pGL3-NFYA promoter plasmid as
template, 1 U Phusion HighFidelity (HF) DNA Polymerase, 0.3 mM of
dNTPs, 1× HF PCR Buffer and 0.5 μM each of the following primers: F
cacttggaaaggggtgggca; R [biotin]gcgagacccgccaatcgg. Multiple reac-
tions were performed to obtain the required amount of probe, which
was then purified using a QIAquick PCR Purification Kit (Qiagen) and
eluted in water. shNF-YA and shCTR HCT116 cells were grown to
70–80% confluence, washed with PBS, scraped and centrifuged.
Nuclear proteins were then extracted with a two-step method: nuclei
were isolated by incubation for 10min in buffer A (10mM HEPES–KOH
pH 7.9, 1.5mM MgCl2, 10mM KCl, 10% glycerol, 0.1% triton X-100,
0.5mM DTT, 1× PIC (Sigma), 1mM PMSF and phosphatase inhibitors)
on ice and centrifuged at 4000 g for 10min. Nuclei were lysed by in-
cubation for 20min on ice in 1× Binding buffer (7mM TrisHCl pH 7.5,
81 mM NaCl, 5 mM MgCl2, 10% glycerol, 1 mM DTT, 1× PIC (Sigma),
0.5 mM PMSF and phosphatase inhibitors) and disrupted by using a
syringe with a 25 gauge needle. Nuclear extracts were then centrifuged
at 14000 rpm, 4 °C for 30min and the supernatant was transferred to a
new tube. The pellet was further extracted with 1× Binding buffer
containing 400mM NaCl: after centrifugation at 14000 rpm, 4 °C for
15min, NaCl concentration was adjusted to 81mM and this extract was
added to the previous one. Protein concentration was determined by
the Bradford assay (Sigma).
Streptavidin-coated agarose beads (S1638, Sigma) were washed
twice in 1× Binding Buffer and pre-cleared for 30min with 1 μg/μl BSA
and 200 μg/ml salmon sperm DNA in 1× binding Buffer. After two
washes in 1× Binding Buffer, pre-cleared beads were associated to
double-stranded biotinylated oligonucleotides (200 pmol/mg of beads)
by incubation for 1 h at 4 °C in 1× Binding Buffer. 1mg of nuclear
extract was then incubated with 100 μl of pre-cleared streptavidin-
coated agarose beads previously associated with the double-stranded
biotinylated NF-YA promoter probe and 100 μg/ml salmon sperm DNA
(D9156, Sigma) for 1 h, 4 °C, on a rotating wheel. Beads were washed
three times in 500 μl 1× Binding Buffer and proteins bound to the
probe were isolated by elution in high-salt buffer (20mM TrisHCl
pH 7.5, 5 mM MgCl2, 1M NaCl). Eluted proteins were then resolved on
Bolt™ 4–12% Bis-Tris Plus Gels (NW04120BOX, Life Technologies) and
stained with Coomassie blue. For GeLCMS sample analysis, 1D-SDS
PAGE lanes were cut in 7 portions and in-gel digested with Sequencing
Grade Modified Trypsin (V5111, Promega) following a standard pro-
cedure [31]. All peptide extracts for each gel portion were pooled, dried
under vacuum and then submitted for analysis to the MS Facility (CIGS,
University of Modena, Italy).
2.7. Mass spectrometry analysis and protein identification
MS analysis was performed on an ESI-Q-TOF Accurate-Mass spec-
trometer (G6520A, Agilent Technologies, Santa Clara, CA, USA),
controlled by MassHunter software (v. B.04.00) and interfaced with a
CHIP-cube to an Agilent 1200 nano-pump. Two biological replicates
were performed for each sample. Raw data, converted from the vendor's
data format into mascot generic format using MassHunter Qualitative
Analysis (v. B.05.00), were searched against Swiss-Prot (v. 2013_04,
20253 entries for Homo sapiens) for peptide sequences and C-RAP
(ftp://ftp.thegpm.org/fasta/cRAP) for contaminants with MASCOT
(Version 2.4, Matrix Science, London, UK). The obtained protein list
was further analyzed with DAVID software in order to point out only
entries relevant for transcriptional regulation. Only proteins identified
in both biological replicates were considered. The ratio between the
protein in shNFYA versus shCTR, normalized according to emPAI (ex-
ponentially modified Protein Abundance Index) method [32], was then
calculated. For further details, see Supplementary information.
2.8. Statistical analysis
At least three independent biological experiments have been per-
formed. The values represented in the histograms are the average of the
biological replicates and the bars indicate the Standard Error of the
Mean (SEM). Statistical significance was analyzed with GraphPad
software using independent Student's t-test between the indicated
samples or between test sample and control when not differently spe-
cified. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
3. Results
3.1. Loss of NF-Y activity increases the expression levels of its subunits
Following the inactivation of the NF-YA subunit through shRNA
lentiviral delivery in human colon-carcinoma HCT116 cells, we com-
pared the levels of the three NF-Y subunits in total protein extracts from
control (shCTR) and NF-YA-abrogated cells (shNF-YA). Both NF-YB and
NF-YC histone-fold subunits were significantly increased in shNF-YA
infected cells (Fig. 1A). The same effect was observed in other human
cancer and immortalized cell lines (Suppl. Fig. 1A). Despite NF-YB and
NF-YC levels were higher in shNF-YA cells, NF-YA depletion led to NF-
YB and NF-YC down-regulation in chromatin enriched extracts, de-
monstrating that NF-YA loss is sufficient to abrogate the DNA binding
ability of the complex (Fig. 1A).
Similarly to shRNA delivery, siRNA-mediated NF-YA knock down
induced an increase of NF-YB and NF-YC protein levels (Fig. 1B). Ad-
ditionally, we analyzed the levels of NF-Y subunits following transient
expression of a dominant negative NF-YA mutant, which titrates the
endogenous NF-YB/NF-YC heterodimer and forms NF-Y complexes
unable to bind DNA [33]. As shown in Fig. 1C, the formation of inactive
NF-Y complexes led to increased NF-YB and NF-YC protein levels.
To determine whether NF-YA was also subject to a negative reg-
ulatory feedback, NF-YB or NF-YC were inactivated through shRNA
delivery. Fig. 1D shows that both shNF-YB and shNF-YC were able to
silence the targeted protein, but in contrast, the expression of the other
non-targeted histone-fold subunit was down-regulated. This suggests
that lack of either NF-YB/NF-YC dimer subunits affects the levels of the
other. Furthermore, we tested whether this behavior could depend on a
corresponding increase in protein degradation and, indeed, the co-
treatment with proteasome and lysosomes activity inhibitors rescued
the expression of the non-targeted histone-like partner in shNF-YB and
shNF-YC cells (Fig. 1D, middle and right panels). Despite NF-YB or NF-
YC knock down does not alter basal NF-YA protein expression, NF-YA
levels increase following protein degradation inhibition in NF-YB and
NF-YC-inactivated cells.
These results highlight that reduced NF-Y activity caused by the loss
of the NF-YA DNA binding subunit, triggers an increase in the levels of
NF-YB/NF-YC proteins. In contrast, the impossibility to form the NF-
YB/NF-YC heterodimer, as the result of NF-YB or NF-YC abrogation,
hampers the stability of the histone-fold partner.
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3.2. NF-Y binds to and regulates NF-YA, NF-YB and NF-YC promoters
To elucidate the mutual regulation between the three NF-Y subunits,
we analyzed the effects of the abrogation of NF-Y activity on the mRNA
levels of its subunits. NF-YA loss significantly increased both NF-YB and
NF-YC transcripts in HCT116, as well as in other human cell lines
(Fig. 2A, left panel, and Suppl. Fig. 1B–C). We analyzed the three NF-YC
splice variants by RT-PCRs with specific primers and related quantifi-
cation: NF-YA depletion induced the rise of 48 kDa and 37 kDa NF-YC
transcripts (Fig. 2B), with the last one being the main translated isoform
Fig. 1. The modulation of individual NF-Y subunits impacts on the expression of all the proteins of the complex. A. Western blot analysis performed on whole cell extracts (WCE) and
chromatin-enriched extracts (chromatin) of control (shCTR) and NF-YA-inactivated (shNF-YA) HCT116 cells (left panel). Proteins expression was quantified normalized to total histone
H3 and reported as fold change of shNF-YA versus shCTR levels, arbitrarily set at 1 (right panel). p values: *** < 0.001, ** < 0.01. B. Protein expression analysis (left panel) of NF-Y
subunits in total extracts of HCT116 cells transfected with control and NF-YA-targeting siRNAs. Quantification of the expression levels of the three NF-Y subunits normalized to actin was
shown as fold change versus siCTR, arbitrarily set at 1 (right panel). C. Western blot analysis of NF-YA, NF-YB and NF-YC expression following transient overexpression of NF-YA-DN
mutant in HCT116 cells. Relative quantification of NF-YA, NF-YB and NF-YC, normalized to actin, was reported as fold change versus cells transfected with the empty vector, arbitrarily
set at 1 (right panel). D. Left panel: Protein expression levels of NF-Y subunits in whole cell extracts of control (shCTR) and NF-YB (shNF-YB) or NF-YC (shNF-YC) HCT116 cells treated or
not with inhibitors of protein degradation. Right panel: Relative quantification of NF-Y expression levels in NF-YB- or NF-YC-inactivated cells versus shCTR. Proteins expression was
quantified normalized to tubulin and reported as fold change versus shCTR levels, arbitrarily set at 1. p values: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001.
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in HCT116 cells (Suppl. Fig. 1D). NF-YB inactivation was able to induce
both NF-YA and NF-YC transcription, while NF-YC loss increased NF-YA
and NF-YB mRNA levels (Fig. 2C). Interestingly, treatments with pro-
tein degradation inhibitors reduced the increase in NF-Y genes tran-
scription, in particular of NF-YB and NF-YC transcripts. This result is
consistent with protein expression analysis (Fig. 1D) and clarifies why
the administration of proteasome/lysosomes inhibitors can only restore
the expression of NF-YB and NF-YC to basal levels.
Overall, these data suggested that NF-Y could be a negative reg-
ulator of its own expression. Regulatory regions of encoding genes were
consequently investigated. UCSC Genome browser was used to identify
H3K27ac enriched regions, as active regulatory elements in NF-YA, NF-
YB and NF-YC genes. Several NF-Y-binding sites are located in the NF-
YA and NF-YB promoters regions (Fig. 3A). As for NF-YC gene, both the
constitutive active P1 promoter and the inducible downstream P2
promoter contain CCAAT boxes [15] (Fig. 3A). Encode ChIP-seq data
and previous results demonstrated that NF-Y binds to NF-YA, NF-YB
and NF-YC promoters [15]. We corroborated these data in HCT116 cells
through ChIP experiments with anti-NF-YA and anti-NF-YB antibodies.
NF-Y binding is enriched at all the NF-Y promoters (Fig. 3B), con-
currently with TBP and H4ac, H3K56ac, H3K4me3 positive-histone
marks (Fig. 3C).
The abrogation of NF-YA through RNAi strongly impaired NF-Y
binding to the identified regulatory regions (Fig. 4A). In an opposite
way, an increase in positive histone marks and TBP binding was ob-
served in NF-YA, NF-YB and NF-YC P1 promoters (Fig. 4B), hinting that
Fig. 2. Individual knock down of NF-Y subunits upregulates
the transcription of the non-targeted ones. A. qRT-PCR
analysis of NF-YA, NF-YB and NF-YC transcripts in shNF-YA
and shCTR cells. Data are presented as log2 mRNA fold
change in NF-Y-inactivated versus control cells. B. Relative
quantification of RT-PCR-amplified transcripts of NF-YC
splice variants normalized to γactin, in control (shCTR) and
NF-YA-inactivated (shNF-YA) cells. The expression levels of
NF-YA, NF-YB and NF-YC transcripts in shCTR cells were
arbitrarily set at 1. C. Analysis of mRNA levels of NF-Y
subunits through qRT-PCR in control (shCTR), NF-YB
(shNF-YB) and NF-YC (shNF-YC) inactivated HCT116 cells
treated or not with protein degradation inhibitors. Data are
presented as log2 mRNA fold change in NF-Y-inactivated
versus control cells. p values: * < 0.05, ** < 0.01,
*** < 0.001, **** < 0.0001.
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NF-Y release from its binding sites alters chromatin accessibility. These
results support the hypothesis that NF-Y negatively regulates the ex-
pression of its subunits at the transcriptional level.
3.3. Mass spectrometry (MS) identified transcription regulators associated
to NF-YA promoter
Since NF-YA function involves DNA binding, appears to be the
complex limiting subunit and its increased expression has been ob-
served in some tumors [34], we aimed to better characterize its tran-
scriptional regulation machinery. In order to identify which proteins
can contribute to the maintenance of basal NF-YA mRNA levels or
trigger NF-YA transcriptional activation following the loss of NF-Y ac-
tivity, shCTR and shNF-YA nuclear extracts were incubated with a PCR-
amplified biotin-labelled NF-YA proximal promoter DNA probe, con-
taining the four CCAAT elements. DNA-protein complexes were ad-
sorbed to streptavidin beads and bound proteins were eluted in high-
salt buffer, resolved through SDS-PAGE and subsequently analyzed by
MS (Fig. 5A). Proteins corresponding to sequenced peptides were
identified with Mascot, filtered based on their annotation in transcrip-
tion-related GO category and then quantified according to the nor-
malized emPAI (exponentially modified Protein Abundance Index)
Fig. 3. NF-Y bounds to open chromatin regulatory regions of NF-YA, NF-YB and NF-YC genes. A. The images are screenshots that link ENCODE NF-YA and NF-YB data in the UCSC
genome browser. Short matches represent direct or inverted CCAAT elements and promoter regions are identified by H3K4me3 and H3K27Ac peaks. B. qChIP analysis of NF-YA, NF-YB
and TBP binding on NF-YA, NF-YB and NF-YC P1 regulatory regions in HCT116 cells. The satellite DNA-rich heterochromatin region of chromosome 11 (Sat Chr11) has been used as
negative control region. C. Enrichment of H4ac, H3K56ac and H3K4me3 chromatin marks in HCT116 cells on NF-YA, NF-YB and NF-YC P1 promoters. Data are presented as %
INPUT ± SD.
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method [32]. Fig. 5B provides the list of selected transcriptional reg-
ulators differentially recruited to the NF-YA probe in the presence or
absence of NF-YA. As expected, NF-YA, NF-YB and NF-YC were only
identified in shCTR sample. The expression profiles analysis was per-
formed with three different cell lines, therefore differences in peptide
counts in control and NF-YA-inactivated cells are unlikely to depend on
different expression levels of the corresponding proteins (Fig. 5C).
3.4. Lamin A is a negative regulator of NF-YA gene transcription
The majority of proteins recruited to the NF-YA promoter in the
absence or presence of NF-YA showed a decrease in the shNF-YA/shCTR
ratio with some proteins detected only when NF-Y was bound to the
promoter (Fig. 5B). This suggests that NF-Y could negatively control the
expression of its subunits through the recruitment of co-repressors.
Among transcriptional regulators exclusive to shCTR extracts, we
identified Lamin A, component of the nuclear lamina with a key role in
chromosome organization and transcriptional regulation [35]. Direct
interaction between NF-Y and Lamin A has been recently described by
the group of G. Piaggio, which showed how an NF-Y-dependent en-
richment of Lamin A in promoters of CCAAT-cell cycle genes is able to
counteract NF-Y transcriptional activity [36]. ChIP analysis in HCT116
cells supported the binding of Lamin A on the NF-YA promoter in
comparison to a negative control region (Fig. 6A). We monitored as a
positive control the TOP2A regulatory region containing a CCAAT-
promoter regulated through NF-YA/Lamin A complex binding [36]. The
same behaviour was observed in Hela cells, where Lamin A binds the
NF-YA promoter together with NF-Y (Suppl. Fig. 2). The decrease in NF-
Y binding induced by shNF-YA corresponded to a lowering in Lamin A
chromatin recruitment, suggesting that NF-Y abrogation may impair
Lamin A association on NF-YA promoter (Fig. 6B). Similarly, NF-YB
knock down by shRNA delivery reduced the binding of Lamin A on NF-
YA promoter (Suppl. Fig. 2B–C).
We then performed transient luciferase assays in HCT116 cells, co-
transfecting the NF-YA 477 bp promoter, cloned upstream to the luci-
ferase gene, together with the expression vectors for NF-YA/NF-YB/NF-
YC (NF-Y trimer) or NF-YA dominant negative mutant (NF-YA-DN), and
Lamin A (Fig. 6C). As expected, NF-Y was able to decrease NF-YA
promoter activity, while the overexpression of NF-YA-DN increased
luciferase expression. Lamin A overexpression reduced of about 40%
NF-YA promoter activity and co-transfections of Lamin A with NF-YA-
DN rescued promoter transcriptional activity, thus corroborating that
the repressive role of Lamin A is mediated by NF-Y binding to CCAAT
boxes.
4. Discussion
Despite a multitude of NF-Y-regulated genes are overexpressed in
cancer cells, mediating cell growth and cancer metabolism, increased
expression levels of NF-Y subunits have been observed only in a handful
of tumors and cancer cells [25,26,34,39,40]. In this study, we showed
that NF-Y subunits are indeed under a transcriptional control played by
NF-Y itself, which could NF-Y relatively stable expression cancer cells.
We demonstrated that the loss of NF-Y complex binding to NF-Y
genes CCAAT-regulatory elements triggers their transcriptional upre-
gulation, also linked to increased chromatin accessibility (Fig. 4). Si-
milarly, in vivo NF-YA knock out in post-mitotic mouse neurons, via
deletion of exons 3–8 out of 9 total coding exons, induced a significant
Fig. 4. Effects of NF-Y loss on chromatin status of NF-Y regulatory regions. A. Binding of NF-YA and NF-YB on regulatory regions of NF-Y genes in control and NF-YA-inactivated cells by
qChIPs. Bars represent NF-Y binding as fold change versus control (shCTR), arbitrarily set at 1. B. qChIP analysis of H4ac, H3K56ac, H3K4me3 and TBP enrichment on NF-Y promoters in
control and NF-YA knocked down cells. Data are presented as binding fold change versus control (shCTR), arbitrarily set at 1. p values are indicated: * < 0.05, ** < 0.01,
*** < 0.001**** < 0.0001.
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increase in NF-YC and mutant NF-YA mRNA [41]. Moreover, in the
Huntington disease R6/2 mouse model, characterized by NF-YA and
NF-YC localization in nuclear inclusions and mutant huntingtin locali-
zation in cortex and striatum, NF-YA and NF-YC mRNA levels were
increased [42]. These patterns clearly suggest the existence of a nega-
tive transcriptional feedback acting as a compensatory system allowing
the fine tuning of NF-Y activity and counteracting functional impair-
ment of NF-Y in vivo.
We focused our work on the transcriptional regulation of NF-YA
subunit, as it contains the DNA binding domain and is the limiting
subunit of the NF-Y complex [5,7,43]. MS analysis of proteins asso-
ciated to the NF-YA CCAAT-promoter in control cells and in NF-YA-
inactivated cells identified several putative transcriptional regulators,
the majority of which are released when NF-Y is lost. This result sug-
gests that the NF-Y complex may repress the NF-YA gene by recruiting
transcriptional co-repressors. Among these of particular interest is
Lamin A, component of nucleoplasmic structures with a demonstrated
role in chromatin organization and transcriptional regulation [44]. The
association of NF-Y and Lamin A has been well described by Cicchilitti
and coworkers, which showed that Lamin A directly interacts with NF-Y
and inhibits NF-Y-dependent gene expression [36]. Our results de-
monstrate that the regulatory region of NF-YA, containing multiple
CCAAT elements, is among NF-Y target genes and is modulated through
NF-Y/Lamin A interaction. Transient transfection experiments with
Lamin A and the dominant negative NF-YA mutant showed that Lamin
A repressive activity on NF-YA promoter is mediated by NF-Y binding to
CCAAT boxes (Fig. 6).
Other transcriptional regulators have been identified among NF-YA
promoter associated proteins in concurrence with NF-Y binding, such as
CREB1, RBBP4 and SP3. CREB1 is a ubiquitous TF, member of the
leucine zipper family, which binds the cAMP-responsive element (CRE)
to modulate gene transcription. Despite CREB1 binding to regulatory
regions has been widely associated to activation of gene transcription,
when recruited through other TFs, it can also exert a transcriptional
activity repressive function [45]. ENCODE Chip-seq data available
through UCSC Genome Browser support our MS results: CREB1 binds,
together with NF-YA and NF-YB, not only to the NF-YA gene CCAAT-
promoter, but also to NF-YB and NF-YC-P1 regulatory regions. Since
Fig. 5. Identification of putative regulators of NF-YA gene
transcription. A. Schematic representation of the DNA pull
down assay used to identify putative transcriptional reg-
ulators of the NF-YA gene by MS. B. Synopsis of MS-iden-
tified proteins associated to transcription-related GO cate-
gory in shCTR and shNF-YA cells. For proteins identified in
both samples, the arrows indicate whether protein binding
to the NF-YA probe is unchanged (↔), decreased (↓, shNF-
YA/shCTR ratio≤ 0.8) or increased (↑, shNF-YA/shCTR
ratio≥ 1.2) following NF-YA loss. The term “ONLY CTR”
indicates proteins exclusive to shCTR extracts. C. The table
represents the expression levels of the indicated genes as
fold change of shNF-YA versus shCTR. Data have been re-
trieved by our published gene expression profiles [18,52].
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CRE motives are not present under CREB1 peaks in NF-YA promoter,
NF-Y could mediate its chromatin recruitment. RBBP4 is a component
of the Mi-2 complex with a role in chromatin remodeling and tran-
scriptional repression [46]. SP3 interacts with HDAC1 and HDAC2, and,
when sumoylated, promotes the recruitment of corepressors, among
which Mi-2 and histone methyltransferases (SETDB1/ESET and SUV4-
20H), thus inhibiting gene transcription [47,48]. Future studies will
address whether and how these predicted regulators control the tran-
scription of NF-Y genes.
Since NF-YA and NF-YC expression has been found to be up-regu-
lated in some solid tumors [20,21,27], it would be important to de-
termine the underlying mechanism leading to NF-Y subunits over-
expression in these cancer cells despite the existing regulatory negative
feedback to preserve basal physiological levels. Two scenarios are
possible: i) the transcriptional regulators of NF-Y genes, such as co-re-
pressors, may be aberrantly expressed in cancer cells and therefore alter
NF-Y expression or ii) the previously described auto-regulatory me-
chanism may be only active in response to acute transient modulation
of NF-Y expression and could be disrupted in chronic conditions. As for
the first hypothesis, deregulated Lamin A/C expression has been ob-
served in various cancers. In particular, colon cancer, basal cell carci-
noma, gastric carcinoma, breast cancer, neuroblastoma and gastro-
intestinal neoplasms present decreased Lamin A/C expression, while its
overexpression was observed in prostate cancer and hepatocellular
carcinoma (for a review see [49]). It would be therefore of interest to
investigate whether a correlation between NF-YA and Lamin A/C ex-
pression exists in normal versus cancer cells and tissues.
In addition to the transcriptional mechanism analysis, our results
demonstrate that also protein stability has an important role in con-
trolling NF-Y expression. In facts, NF-YB and NF-YC subunits are de-
graded when their histone-fold partner is down-regulated. We already
described that the subcellular localization of NF-YB and NF-YC depends
on their interaction. Specifically, we showed that nuclear localization of
NF-YC is regulated via heterodimerization with NF-YB [50], therefore
NF-YB knock down likely impairs NF-YC nuclear shuttling and redirects
it towards degradation. Similarly, NF-YC protects NF-YB from de-
gradation. While the post-translational mechanisms controlling NF-YA
stability have been described [10], NF-YB and NF-YC post-translational
processes remain to be investigated. We may speculate that the NF-YB/
NF-YC heterodimer assembly may be able to mask specific residues
involved in proteasome or lysosome degradation.
5. Conclusions
Our data support the existence of an autoregulatory loop controlling
the expression of the transcription factor NF-Y, based on mutual tran-
scriptional and post-translational control of its subunits expression.
Taking into consideration the key role of NF-Y in multiple physiological
and pathological processes, we believe this knowledge will be instru-
mental when analyzing cell transformation processes and cancer-
Fig. 6. Lamin A binds to and represses NF-YA promoter activity. A. qChIP analysis of the binding of NF-YA and Lamin A on the regulatory region of the NF-YA gene. Data are reported as
%INPUT ± SD. Topoisomerase IIα promoter and satellite region of chromosome 11 (Sat Chr11) have been used as positive and negative control regions, respectively. B. Effects of NF-YA
abrogation on chromatin binding of NF-YA and Lamin A, determined by qChIP analysis in HCT116 cells. Data are presented as binding fold change in the absence of NF-YA (shNF-YA)
versus control cells (shCTR), arbitrarily set at 1. C. Transient luciferase assay performed in HCT116 cells: the NF-YA promoter-LUC vector has been co-transfected with the NF-Y
heterotrimer (composed by NF-YAs isoform, NF-YB and NF-YC 37 kDa isoform) or the NF-YA dominant negative mutant (NF-YA-DN), Lamin A or its respective empty vector (pCMV3).
Data are presented as RLU fold change versus the basal activity of the promoter (CTR). D. Western blot analysis of Lamin A expression in HCT116 cells transiently transfected with empty-
or Lamin A-expressing vector. Tubulin was used as loading control.
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related processes where NF-Y activity is altered.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbagrm.2018.02.008.
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